Ventana rejects Roche takeover bid
This article was originally published in The Gray Sheet
Tissue-based diagnostics firm Ventana rejects Roche's $3 billion hostile takeover bid as "inadequate" July 11. Roche, which hopes to pair the technology with its targeted cancer drugs for advanced personalized medicine, had announced the offer June 25. The diversified drug and diagnostics giant responded to Ventana's dismissal of the offer in a same-day letter, stating that if there is "additional information that would support a valuation in excess of our offer, we would be willing to consider it in a negotiation." Roche adds that if a negotiated transaction is not possible, it will continue with its $75-per-share cash tender offer, launched June 27, and consider taking the issue directly to Ventana's shareholders at the firm's 2008 annual meeting. "Such action may include the nomination of new directors to Ventana's board and/or proposals to amend Ventana's bylaws," Roche says (1"The Gray Sheet" July 2, 2007, p. 10)...
You may also be interested in...
Roche's $3 billion hostile takeover bid for Ventana Medical Systems is aimed at providing the drug and diagnostics giant with platform technology for tissue-based diagnostic tests to pair with targeted cancer drugs, the company says
India has removed export restrictions on APIs and formulations imposed by the country in March. However, certain measures have been kept in place to ensure that domestic requirements are met for in-demand products such as hydroxychloroquine and paracetamol.
EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.